SCHEMBL2902022

SCHEMBL2902022

O=C1OC(c2ccccc2)CN1Cc1ccc(N2CCN(Cc3ccccn3)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.52
ALDH1A1 P00352 5/20 0.52
LMNA P02545 2/20 0.52
GFER P55789 1/20 0.52
NPSR1 Q6W5P4 1/20 0.46
TRPV6 Q9H1D0 1/20 0.43
FADS1 O60427 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OPRL1 P41146 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DRD4 P21917 4/20 0.40
DRD2 P14416 3/20 0.40
DRD3 P35462 2/20 0.40
EGLN1 Q9GZT9 1/20 0.40
HTR1A P08908 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902024 1.00 KDM4E (0.52) KDM4EALDH1A1LMNAGFERNPSR1
SCHEMBL2899033 0.93 KDM4E (0.47) KDM4EALDH1A1LMNAGFERNPSR1
SCHEMBL2899032 0.93 KDM4E (0.47) KDM4EALDH1A1LMNAGFERNPSR1
SCHEMBL2893733 0.93 TRPV6 (0.47) KDM4EALDH1A1LMNANPSR1TRPV6
SCHEMBL2893732 0.93 TRPV6 (0.47) KDM4EALDH1A1LMNANPSR1TRPV6
SCHEMBL13086217 0.90 KDM4E (0.45) KDM4EALDH1A1LMNAGFERNPSR1
SCHEMBL2901483 0.87 POLB (0.47) TRPV6FADS1OPRL1SMN1; SMN2DRD4
SCHEMBL2901482 0.87 POLB (0.47) TRPV6FADS1OPRL1SMN1; SMN2DRD4
SCHEMBL4328591 0.86 DRD4 (0.54) FADS1DRD4DRD2DRD3GRM2
SCHEMBL4328587 0.86 DRD4 (0.54) FADS1DRD4DRD2DRD3GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-01-08 US claimed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US claimed
US-7816354-B2 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2010-10-19 US disclosed
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-01-08 US disclosed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM2 KDM4E 3351/4885ALDH1A1 1329/4885LMNA 4716/4885
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 KDM4E 3351/4885ALDH1A1 1329/4885LMNA 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.